Gamida Cell Has Success With Its Nicord Blood Cancer Medication

Israel’s Gamida Cell, a developer of cell therapy technologies and products for transplantation and adaptive immune therapy, announced that the first person has been successfully transplanted with cryopreserved More...

Medivation takes up $335 million Curetech licensing option

– The agreement gives Medivation the license to develop and commercialize Curetech’s pidilizumab cancer treatment. –   Medivation has decided to exercise the option granted it by Curetech More...

BioLineRX signs Novartis strategic cooperation deal

– Novartis will invest $10 million in BioLineRX for a 12.8% stake. They will select three projects for joint development. –   Drug development company BiolineRX Ltd. (Nasdaq: BLRX); TASE:BLRX) More...

Clal Biotech Sells Pidilizumab Cancer Treatment Rights to Medivation

Israel’s Clal Biotechnology Industries has sold the exclusive worldwide commercialization rights for its cancer treatment pidilizumab to the American company Medivation. The rights are held by Clal subsidiary More...